Member Info for Sangijuelas1

They are talking about Tocilizumab and Budesonide.
There is a whole world beyond Avacta you know

Why would they need to raise capital on Nasdaq if we are told they are going to earn gazillions from the LFTs?
You lot need to get your story straight!

Do you really think they are talking about Avacta?

FFS it's for Tocilizumab and Budesonide. They are running trials now

PL75 You have spent the last couple of months claiming that all will be well once CV is done. That anyone out at that time will be left out of the massive gains the day of the RNS.

Now do you think you were right or wrong about that?

I am not going to repeat what he said as I don't want to get banned as well

He suggested he had inside info

Wow looks like he had his account shut down

Actually not permanent but several days

Yeah I saw it and suggested he shouldn't post stuff like that as a guy got a permanent ban for saying stuff like that on Avacta.
Didn't report though as thought would give him benefit of the doubt

A little because clearly oversold

You know you can get permanently banned if you get reported

So you are acting on inside information?

You lot are not investors. You are SP speculators.
Investors look at long term prospects.
And how do you know what Mints strategy is?

Total volume today equates to under £200k.
That's retail investors buying and selling.

Are all shooting yourselves in the foot with all the negativity.
Anyone seeing the SP down that pops in here to have a look at the chat would run a mile.

I dipped my toe in here yesterday in part due to Alex Stevenson of 4D being on the board.

CLNs ever an issue for Tesla. Small pharmas have to get money from somewhere

If Mint are converting it's because they anticipate that the price will rise. It's not rocket science.

Wondered if anyone else had taken a look at C4XD.

Our very own Alex Stevenson is a non executive director there.

I have dipped my toe in there today.

Michael, I think there's a point with the vaccine program where 4D hand over up to 3 optimised candidates to Merck for clinical development. I think we are at the point where these candidates are being narrowed down from a number of possible ones. But Merck should be doing the heavy lifting there as I understand it.

I think the job roles relate to the talk of 2nd generation oncology drugs that have been discussed previously on the investor webinars and maybe other neurodegenerative conditions